Lumexa Imaging Holdings

LMRI

Market cap $904M

RALEIGH, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ: LMRI), one of the nation's largest providers of outpatient imaging services, today announced the formation of a strategic joint venture with Hospital for Special Surgery (HSS), world leader in musculoskeletal health.

Lumexa Imaging Holdings, Inc. (LMRI) Q1 2026 Earnings Call Transcript

Lumexa Imaging NASDAQ: LMRI reported first-quarter results that management said were in line with expectations, as growth in advanced imaging modalities helped offset seasonal volume pressure and weather-related disruptions.

RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, today announced results for the first quarter ended March 31, 2026, and reiterated full year 2026 guidance.

RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ: LMRI), one of the nation's largest providers of outpatient imaging services, today announced the addition of four new locations in 2026 as part of its continued execution against a disciplined, multi-channel growth strategy.

Shares of Lantheus Holdings were added after the company received FDA approval of its key product TruVu. We used recent weakness as an opportunity to initiate a position in Talen Energy, an independent power producer whose portfolio includes the Susquehanna nuclear plant and other dispatchable generation assets. We exited Cactus as we lost confidence that its major growth lever, expansion into the Middle East, would play out in 2026 amid the escalating conflict in the region.

RALEIGH, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ: LMRI), one of the nation's largest providers of outpatient imaging services, today announced it will release its first quarter 2026 financial and operational results after market close on Tuesday, May 12, 2026.

Proven healthcare growth leader to drive disciplined, profitable expansion and scale across Lumexa Imaging's platform Proven healthcare growth leader to drive disciplined, profitable expansion and scale across Lumexa Imaging's platform

Lumexa Imaging Holdings, Inc. (LMRI) Q4 2025 Earnings Call Transcript

Lumexa Imaging remains a Buy, with Q4 2025 results clarifying the medium-term growth and margin trajectory. Advanced imaging volumes and mix are rising, driving superior unit economics and margin expansion; FastScan rollout is a key throughput catalyst. De novo center openings reached a record, with rapid breakeven timelines supporting compounding organic growth and future margin upside.